Teva’s Generic EpiPen U.S. Launch Still Stalled Five Months After Approval

Short supply is missed opportunity for Israeli drug maker in $750 million market

Reuters
Send in e-mailSend in e-mail
FILE PHOTO: EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S. August 24, 2016.
FILE PHOTO: EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S. August 24, 2016.Credit: \ Jim Bourg/ REUTERS

Comments